Zars, Inc. Files Registration Statement for Initial Public Offering SALT LAKE CITY, June 11 -- ZARS, Inc., announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company. The number of shares of common stock and price per share to be sold have not yet been determined. Cowen and Company and CIBC World Markets are joint book running managers for the offering. Leerink Swann & Company and Susquehanna Financial Group, LLLP are comanagers. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering will be made only by means of a prospectus. When available, a copy of the prospectus for the above offering can be obtained by eligible investors from their Cowen and Company sales representative, from the offices of Cowen and Company, LLC c/o ADP., 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Dept. (631) 254-7106 or from CIBC World Markets Corp., Attn: USE Prospectus Department, 425 Lexington Ave, 5th floor, New York, New York 10017, (866) 895-5637. About ZARS, Inc. ZARS, Inc. is a specialty pharmaceutical company focused on the development and commercialization of topically applied drugs using its proprietary drug delivery technologies, with an initial focus on pain management. ZARS has developed a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery (CHADD) and its phase-changing cream (Peel and DuraPeel) technologies. The Company's products and product candidates include two products that have been approved for marketing (Pliaglis and Synera), one product candidate for which it plans to begin Phase 3 clinical trials in the third quarter of 2007 (ThermoProfen) and two product candidates which are in Phase 1 clinical trials.